Mobile

Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC- 0980 in combination with fulvestrant, in patients with advanced br...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-023763-17

Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC- 0980 in combination with fulvestrant, in patients with advanced breast cancer for whom treatment with an aromatase inhibitor is not effective

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To evaluate the efficacy (as measured by PFS) of fulvestrant + GDC-0941 versus fulvestrant + placebo •To evaluate the safety of fulvestrant+GDC 0941 and fulvestrant + GDC 0980 versus fulvestrant + placebo

Critère d'inclusion

  • Advanced or metastatic breast cancer resistant to aromatase inhibitor therapy

Liens